Cecilia Brown

DocwireNews

Tezepelumab reduced asthma exacerbations and improved lung function more than placebo in patients with severe, uncontrolled asthma who were former smokers or never smokers, according to a recent study.Mario Castro, MPH, MD, of the University of Kansas School of Medicine, and colleagues conducted the research because &ldquo;smoking is associated with more severe asthma symptoms and reduced treatment response,&rdquo; and while &ldquo;smoking cessation can improve symptoms, little is known about the efficacy of biologic treatment in former smokers.&rdquo;Dr. Castro and colleagues conducted a post hoc analysis of phase 3 NAVIGATOR study data to assess the effectiveness of tezepelumab, a human monoclonal antibody that blocks thymic stromal lymphopoietin, in patients who were former smokers and patients who were never smokers.The NAVIGATOR study was a randomized, double-blind, placebo-controlled multicenter study. The study comprised 1059 patients aged 12 to 80 years who were not current smokers. Patients who stopped smoking, vaping, or using e-cigarettes at least 6 months before their first visit were eligible if they had a smoking history of less than 10 pack years. All patients were receiving medium-to-high doses of inhaled corticosteroids and at least 1 additional controller medication with or without oral corticosteroids.Patients who formerly smoked comprised 20% of the study population, with 99 receiving tezepelumab and 110 receiving the placebo. A higher proportion of patients who formerly smoked were male, had experienced more than 2 asthma exacerbations, had lower baseline fractional exhaled nitric oxide levels, and were receiving maintenance oral corticosteroids, compared with patients who never smoked.Dr. Castro and colleagues assessed the annualized asthma exacerbation rate by measuring the prebronchodilator forced expiratory volume at baseline through week 52.Tezepelumab reduced the annualized asthma exacerbation rate by 48% (95% CI, 21-65) more than placebo in patients who formerly smoked, while it reduced the annualized asthma exacerbation rate by 58% (95% CI, 48-66) more than placebo in patients who never smoked.The annualized asthma exacerbation rate over 1 year in patients receiving placebo was higher in patients who formerly smoked (2.58; 95% CI, 1.97-3.39) than in patients who never smoked (1.98; 95% CI, 1.71-2.28).Tezepelumab led to a greater improvement from baseline to week 52 in prebronchodilator forced expiratory volume in 1 second than placebo in patients who formerly smoked and those who never smoked.&ldquo;This analysis demonstrates the efficacy of tezepelumab in a broad population of patients with severe, uncontrolled asthma, including patients who were former smokers and who had never smoked,&rdquo; Dr. Castro and colleagues concluded.Kraft M, L Colice GL, Ambrose C, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma grouped by number of additional asthma controller medications: results from the phase 3 NAVIGATOR study. Chest. 2022;162(4):A11-A12. doi:10.1016/j.chest.2022.08.012

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Tezepelumab Reduces Asthma Exacerbations in Patients Who Smoked, Never Smoked

Asthma

Tezepelumab reduced asthma exacerbations and improved lung function more than placebo in patients with severe, uncontrolled asthma who were former smokers or never smokers, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe